First Time Loading...
V

VIVA Biotech Holdings
HKEX:1873

Watchlist Manager
VIVA Biotech Holdings
HKEX:1873
Watchlist
Price: 0.79 HKD 25.4% Market Closed
Updated: May 17, 2024

VIVA Biotech Holdings
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

VIVA Biotech Holdings
Cost of Revenue Peer Comparison

Comparables:
603259
300759
2269
300347
1548

Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
V
VIVA Biotech Holdings
HKEX:1873
Cost of Revenue
-¥1.4B
CAGR 3-Years
-53%
CAGR 5-Years
-68%
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Cost of Revenue
-¥23.6B
CAGR 3-Years
-28%
CAGR 5-Years
-30%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Cost of Revenue
-¥7.6B
CAGR 3-Years
-28%
CAGR 5-Years
-29%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Cost of Revenue
-¥10.2B
CAGR 3-Years
-49%
CAGR 5-Years
-46%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Cost of Revenue
-¥4.5B
CAGR 3-Years
-35%
CAGR 5-Years
-26%
CAGR 10-Years
-36%
Genscript Biotech Corp
HKEX:1548
Cost of Revenue
-$430m
CAGR 3-Years
-47%
CAGR 5-Years
-43%
CAGR 10-Years
N/A

See Also

What is VIVA Biotech Holdings's Cost of Revenue?
Cost of Revenue
-1.4B CNY

Based on the financial report for Dec 31, 2023, VIVA Biotech Holdings's Cost of Revenue amounts to -1.4B CNY.

What is VIVA Biotech Holdings's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-68%

Over the last year, the Cost of Revenue growth was 9%. The average annual Cost of Revenue growth rates for VIVA Biotech Holdings have been -53% over the past three years , -68% over the past five years .